Minerva Neurosciences (NERV) Other Non-Current Liabilities (2013 - 2026)
Minerva Neurosciences' (NERV) quarterly Other Non-Current Liabilities came in at $60.0 million in Q1 2026, little changed YoY from $60.0 million in Q1 2025, and little changed on a QoQ basis from $60.0 million in Q4 2025.
Analysis
Minerva Neurosciences (NERV) Other Non-Current Liabilities (2013 - 2026) Analysis & Trends
Minerva Neurosciences (NERV) has 11 years of Other Non-Current Liabilities data on file, last reported at $60.0 million in Q1 2026.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $60.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.0 million (changed 0.0% YoY) and the FY2025 annual result came in at $60.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities held at $60.0 million in Q1 2026, from $60.0 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $86.6 million in Q2 2024 to a low of $60.0 million in Q3 2024.
- A 5-year average of $70.6 million and a median of $70.9 million in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities climbed 11.37% — and 2025, when it tumbled 30.7%.
- Tracing NERV's Other Non-Current Liabilities over 5 years: stood at $73.7 million in 2022, then rose by 11.23% to $82.0 million in 2023, then fell by 26.84% to $60.0 million in 2024, then changed by 0.0% to $60.0 million in 2025, then changed by 0.0% to $60.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $60.0 million (Q1 2026), $60.0 million (Q4 2025), and $60.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Minerva Neurosciences | 207.37 Mn | 207.37 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 232.69 Mn |
| Mar 31, 2026 | 278.60 Mn |
| Dec 31, 2025 | 171.46 Mn |
| Sep 30, 2025 | 60.00 Mn |
| Jun 30, 2025 | 60.00 Mn |
| Mar 31, 2025 | 60.00 Mn |
| Dec 31, 2024 | 60.00 Mn |
| Sep 30, 2024 | 60.00 Mn |
| Jun 30, 2024 | 86.58 Mn |
| Mar 31, 2024 | 84.27 Mn |
| Dec 31, 2023 | 82.02 Mn |
| Sep 30, 2023 | 79.83 Mn |
| Jun 30, 2023 | 77.74 Mn |
| Mar 31, 2023 | 75.71 Mn |
| Dec 31, 2022 | 73.73 Mn |
| Sep 30, 2022 | 71.81 Mn |
| Jun 30, 2022 | 69.93 Mn |
| Mar 31, 2022 | 68.11 Mn |
| Dec 31, 2021 | 66.33 Mn |
| Sep 30, 2021 | 64.59 Mn |